
Bio-Rad Laboratories is talks to merge with Qiagen in a deal that may be valued at more than $10 billion, The Wall Street Journal reported on Monday, citing people familiar with the matter.
While talks have been ongoing for some time, an agreement isn’t likely for a few weeks and the deal still may fall through, according to the report.
Spokespersons at both companies weren’t immediately available to comment when contacted by MedTech Dive.
Hercules, Calif.-based Bio-Rad makes various products for the life science research and clinical diagnostic markets. It has a market capitalization of just under $12 billion. Qiagen is a Germany-based diagnostics company, with a market capitalization of about $10 billion.
Thermo Fisher attempted to buy Qiagen in 2020 in a deal that was initially valued at $11.5 billion. That transaction fell apart after failing to secure support from Qiagen’s shareholders. Thermo Fisher went on to acquire research contractor PPD last year for $17.4 billion.
The report of a Bio-Rad tie up with Qiagen comes amid a lull of medtech mergers and acquisitions following a spending spree last year. Notable acquisitions this year include Stryker’s $3 billion purchase of Vocera Communications, ResMed’s approximately $1 billion pickup of MediFox Dan and Becton Dickinson’s $1.53 billion purchase of Parata Systems.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
House Passes ‘Take It Down Act,’ the First Major AI-Related Federal Regulation
Apr 29, 2025 by
CPI
Michigan Sues Express Scripts, Prime Therapeutics for Alleged Price-Fixing Scheme
Apr 29, 2025 by
CPI
Tech Rivals Testify as FTC Antitrust Trial Against Meta Enters Defining Phase
Apr 29, 2025 by
CPI
Spanish Judge Investigates Nationwide Blackout as Possible Cyber Threat
Apr 29, 2025 by
CPI
Trump Administration Pushes EU to Delay AI Regulations
Apr 29, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Mergers in Digital Markets
Apr 21, 2025 by
CPI
Catching a Killer? Six “Genetic Markers” to Assess Nascent Competitor Acquisitions
Apr 21, 2025 by
John Taladay & Christine Ryu-Naya
Digital Decoded: Is There More Scope for Digital Mergers In 2025?
Apr 21, 2025 by
Colin Raftery, Michele Davis, Sarah Jensen & Martin Dickson
AI In the Mix – An Ever-Evolving Approach to Jurisdiction Over Digital Mergers in Europe
Apr 21, 2025 by
Ingrid Vandenborre & Ketevan Zukakishvili
Antitrust Enforcement Errors Due to a Failure to Understand Organizational Capabilities and Dynamic Competition
Apr 21, 2025 by
Magdalena Kuyterink & David J. Teece